No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Carmafil Launches Newly Designed Guidewire Bowl – Now Commercially Available

Editor: What To Know

  •   The patent-pending Carmafil guidewire bowl solves the problem of having a tangle of wires and catheters at the bottom.
  •   The new bowl has a staircase design along the inside wall which segregates the wires to make it easier to retrieve them.
  • A variety of doctors (neurosurgeons, neurologists, radiologists, cardiologists, vascular surgeons, and cardiac surgeons) use catheters and wires to fix blood vessel problems in the body through a minimally invasive approach.

April 8, 2021

Carmafil, LLC is excited to announce the launch of a newly designed guidewire bowl that helps specialists be more efficient during endovascular procedures.

Developed by vascular/endovascular neurosurgeon Dr. Cargill Alleyne, this uniquely designed product is now available for commercial use.

A variety of doctors (neurosurgeons, neurologists, radiologists, cardiologists, vascular surgeons, and cardiac surgeons) use catheters and wires to fix blood vessel problems in the body through a minimally invasive approach.  These filaments are housed in a bowl filled with saline to keep them hydrated.  The patent-pending Carmafil guidewire bowl solves the problem of having a tangle of wires and catheters at the bottom.  The new bowl has a staircase design along the inside wall which segregates the wires to make it easier to retrieve them.  Other key features are:

–          It holds up to 4 wires or catheters

–          The wires or catheters can easily be retrieved with one hand

–          It reduces potential contamination during retrieval

–          The light blue color facilitates visualization of the wires in dim lighting

–          It was designed by a practicing neuro interventionalist and an engineer.

“As a busy clinician, I’m constantly seeking ways to increase efficiency in the operating room and the angiography suite.  This modification to the standard guidewire bowl goes a long way toward that end” says co-inventor and company CEO Dr. Cargill Alleyne.  He is a dually trained, vascular/endovascular neurosurgeon in private practice at University Hospital Augusta Back in Augusta, GA. Dr. Alleyne is the former Chairman and Residency Program Director of the Department of Neurosurgery, Medical College of Georgia, Augusta University.  The other co-founder Mahmoud Baniasadi, Ph.D. is an Assistant Professor in the Allen E. Paulson College of Engineering and Computing, Department of Manufacturing Engineering at Georgia Southern University.

Carmafil, LLC manufactures a unique guidewire bowl which was developed from the collaboration of a dually trained open/endovascular neurosurgeon and an engineer.

The company has been nationally certified as a Minority Business Enterprise by the Georgia Minority Supplier Development Council.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy